Dynamic chromatin association of IκBα is regulated by acetylation and cleavage of histone H4.


Journal

EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049

Informations de publication

Date de publication:
04 08 2021
Historique:
revised: 27 05 2021
received: 15 02 2021
accepted: 09 06 2021
pubmed: 6 7 2021
medline: 1 6 2022
entrez: 5 7 2021
Statut: ppublish

Résumé

IκBs exert principal functions as cytoplasmic inhibitors of NF-kB transcription factors. Additional roles for IκB homologues have been described, including chromatin association and transcriptional regulation. Phosphorylated and SUMOylated IκBα (pS-IκBα) binds to histones H2A and H4 in the stem cell and progenitor cell compartment of skin and intestine, but the mechanisms controlling its recruitment to chromatin are largely unknown. Here, we show that serine 32-36 phosphorylation of IκBα favors its binding to nucleosomes and demonstrate that p-IκBα association with H4 depends on the acetylation of specific H4 lysine residues. The N-terminal tail of H4 is removed during intestinal cell differentiation by proteolytic cleavage by trypsin or chymotrypsin at residues 17-19, which reduces p-IκBα binding. Inhibition of trypsin and chymotrypsin activity in HT29 cells increases p-IκBα chromatin binding but, paradoxically, impaired goblet cell differentiation, comparable to IκBα deletion. Taken together, our results indicate that dynamic binding of IκBα to chromatin is a requirement for intestinal cell differentiation and provide a molecular basis for the understanding of the restricted nuclear distribution of p-IκBα in specific stem cell compartments.

Identifiants

pubmed: 34224210
doi: 10.15252/embr.202152649
pmc: PMC8344903
doi:

Substances chimiques

Chromatin 0
Histones 0
Nucleosomes 0
NF-KappaB Inhibitor alpha 139874-52-5

Banques de données

GEO
['GSE131187', 'GSE167087']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e52649

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM085490
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 The Authors.

Références

J Cell Sci. 1997 Feb;110 ( Pt 3):369-78
pubmed: 9057089
Cell. 2008 Oct 17;135(2):284-94
pubmed: 18957203
Sci Rep. 2020 Sep 30;10(1):16153
pubmed: 32999373
Bioessays. 2015 Jan;37(1):70-9
pubmed: 25350939
J Biol Chem. 2003 Aug 22;278(34):32227-35
pubmed: 12794074
Methods Enzymol. 2004;375:23-44
pubmed: 14870657
Cell. 1993 Mar 12;72(5):729-39
pubmed: 8453667
EMBO Rep. 2020 Jun 4;21(6):e49708
pubmed: 32270911
Nat Struct Mol Biol. 2014 Oct;21(10):927-36
pubmed: 25218447
Nucleic Acids Res. 2021 Jan 25;49(2):791-804
pubmed: 33398338
Cancer Cell. 2013 Aug 12;24(2):151-66
pubmed: 23850221
PLoS One. 2012;7(11):e50300
pubmed: 23209700
Mol Cell. 1998 Aug;2(2):233-9
pubmed: 9734360
Mol Cell Biol. 2010 Oct;30(20):4901-21
pubmed: 20696840
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
J Immunol. 2005 Mar 15;174(6):3650-7
pubmed: 15749903
Curr Opin Immunol. 2013 Feb;25(1):1-3
pubmed: 23452839
Front Biosci. 2001 Oct 01;6:D1256-63
pubmed: 11578953
Genome Biol. 2014;15(12):550
pubmed: 25516281
Chem Rev. 2015 Mar 25;115(6):2376-418
pubmed: 25688442
Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16537-42
pubmed: 15536134
J Mol Biol. 2018 Sep 14;430(18 Pt B):3051-3067
pubmed: 30009770
Nature. 2010 Aug 26;466(7310):1115-9
pubmed: 20740013
Methods Mol Biol. 1999;112:531-52
pubmed: 10027275
Stem Cell Res. 2014 Jul;13(1):123-34
pubmed: 24874291
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Biophys J. 2013 Mar 5;104(5):1081-8
pubmed: 23473491
Genes Dev. 2016 Jan 15;30(2):208-19
pubmed: 26744418
J Biol Chem. 2002 Mar 8;277(10):8749-54
pubmed: 11773058
EMBO Rep. 2021 Aug 4;22(8):e52649
pubmed: 34224210
Cell. 2012 Mar 30;149(1):214-31
pubmed: 22464331
J Allergy Clin Immunol. 2017 Aug;140(2):474-485
pubmed: 28108335

Auteurs

Laura Marruecos (L)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Joan Bertran (J)

Faculty of Science and Technology, Bioinformatics and Medical Statistics Group, University of Vic - Central University of Catalonia, Barcelona, Spain.

Daniel Álvarez-Villanueva (D)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

María Carmen Mulero (MC)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
Department of Chemistry & Biochemistry, University of California San Diego, La Jolla, CA, USA.

Yolanda Guillén (Y)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Luis G Palma (LG)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Martin Floor (M)

Faculty of Science and Technology, Bioinformatics and Medical Statistics Group, University of Vic - Central University of Catalonia, Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain.

Anna Vert (A)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Sara Arce-Gallego (S)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Irene Pecharroman (I)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Laura Batlle (L)

Tissue Engineering Unit. Center for Genomic Regulation (CRG), Barcelona, Spain.

Jordi Villà-Freixa (J)

Faculty of Science and Technology, Bioinformatics and Medical Statistics Group, University of Vic - Central University of Catalonia, Barcelona, Spain.
Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain.

Gourisankar Ghosh (G)

Department of Chemistry & Biochemistry, University of California San Diego, La Jolla, CA, USA.

Anna Bigas (A)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Lluís Espinosa (L)

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH